Talk:Aflibercept

Approvals

So there's details on a date of approval ofr use in DM/DMO, but not where. UK spelling of "oedema" so that suggests the EMA gave the thumbs up and the EC approved it -- but it could instead be the FDA's approval and date. Sucks not to be in the US or Europe though -- those places are irrelevant when it comes to this, it seems. — Preceding unsigned comment added by 213.107.159.3 (talk) 21:14, 27 August 2015 (UTC)

Cost

Aflibercept (Zaltrap) is so expensive that, at the urging of Peter Bach, Memorial-Sloan Kettering decided not to use it.

http://nymag.com/news/features/cancer-drugs-2013-10/ The Cost of Living New drugs could extend cancer patients’ lives—by days. At a cost of thousands and thousands of dollars. Prompting some doctors to refuse to use them. By Stephen S. Hall New York Magazine Oct 20, 2013 --Nbauman (talk) 16:45, 21 October 2013 (UTC)

ziv-aflibercept is cheaper (but slightly different formulation) - See Another Cancer Drug May Be Effective Bargain for DME Treatment which says/quotes ""Ziv-aflibercept, with its lower cost per injection, could be a potential cost-effective substitute for aflibercept (Eylea), in the same way that bevacizumab is a cost-effective substitute for ranibizumab (Lucentis)," Soheilian said. "It has the same molecular structure as aflibercept. Although they have differences in the preparation and drug formulation, these two are members of VEGF trap products, which act as soluble decoy receptors, neutralizing all VEGF-A isoforms."" - Rod57 (talk) 18:04, 17 November 2017 (UTC)

Can anybody elaborate follwoing wordings

"In 2017, injections of aflibercept (HCPCS code J0178) were responsible for the most billing to Medicare Part B, at $2.36 billion." How much was used for cancer treatment, and how much was used for eye treatment? Thanks. ThomasYehYeh (talk) 02:37, 30 December 2023 (UTC)